Chemomab Therapeutics Statistics
Total Valuation
CMMB has a market cap or net worth of $16.13 million. The enterprise value is $6.07 million.
Important Dates
The last earnings date was Thursday, November 20, 2025, before market open.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CMMB has 6.16 million shares outstanding. The number of shares has increased by 63.31% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 6.16M |
| Shares Change (YoY) | +63.31% |
| Shares Change (QoQ) | +6.65% |
| Owned by Insiders (%) | 14.06% |
| Owned by Institutions (%) | 10.97% |
| Float | 5.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.49
| Current Ratio | 10.49 |
| Quick Ratio | 10.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -73.21% and return on invested capital (ROIC) is -48.43%.
| Return on Equity (ROE) | -73.21% |
| Return on Assets (ROA) | -40.61% |
| Return on Invested Capital (ROIC) | -48.43% |
| Return on Capital Employed (ROCE) | -96.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$504,250 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -63.31% |
| Shareholder Yield | -63.31% |
| Earnings Yield | -62.54% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CMMB is $26.50, which is 919.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.50 |
| Price Target Difference | 919.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -48.03% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 26, 2025. It was a reverse split with a ratio of 1:4.
| Last Split Date | Aug 26, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |